Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)
| Status: | Archived |
|---|---|
| Conditions: | Neurology, Multiple Sclerosis |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2009 |
| End Date: | December 2011 |
Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)
We hypothesize that corticotropin or adrenocorticotrophic hormone (ACTH), administered as
Acthar Gel® (MANUFACTURER NAME) is effective in the control of clinical disease activity as
a pulse therapy for relapsing-remitting MS when added to standard treatment with
beta-interferon.
We wish to determine whether ACTH, when administered as clustered monthly intramuscular
injections (monthly pulse therapy) as add-on to beta-interferons, may be a safe and
effective alternative to monthly pulse therapy with MP. In addition, we hypothesize that
pulse therapy with ACTH alters immune function to favor a regulatory, rather than a
pro-inflammatory T cell environment.
We found this trial at
1
site
Click here to add this to my saved trials
